Objective: To use power Doppler sonography (PDS) to evaluate changes in synovial perfusion induced by adalimumab in the wrist joints of patients with rheumatoid arthritis. Methods: 48 wrists of 24 patients (18 women and 6 men) were examined. Despite prior treatment with disease-modifying antirheumatic drugs, including methotrexate, patients with clinically active rheumatoid arthritis were recruited in two rheumatological centres to receive 40 mg adalimumab subcutaneously every other week. Clinical, laboratory and PDS assessments were carried out at 0, 2, 6 and 12 weeks. Clinical and laboratory measurements of disease activity included physician’s global assessment of disease activity, erythrocyte sedimentation rate and serum levels of C reactive protein. The Disease Activity Score for 28 joints (DAS28) was calculated. PDS signal was scored from 0 to 3 according to the overall expression of PDS findings at the wrists. Results: A significant reduction in both clinical (p,0.001) and PDS findings (p,0.001) was found at all follow-up examinations. A tendency to positive correlation (Spearman’s r = 0.382; p = 0.067) was shown between reduction in PDS score and improvement in DAS28 at week 2 examination. Conclusion: PDS detected a rapid and significant reduction in synovial perfusion at the wrist joints of patients with rheumatoid arthritis receiving adalimumab. Ongoing follow-up will provide further information regarding the persistence of considerable reduction in PDS signal score and its correlation with DAS28

Power Doppler sonography monitoring of synovial perfusion at wrist joint in rheumatoid patients treated with adalimumab.

IAGNOCCO, Annamaria;
2006-01-01

Abstract

Objective: To use power Doppler sonography (PDS) to evaluate changes in synovial perfusion induced by adalimumab in the wrist joints of patients with rheumatoid arthritis. Methods: 48 wrists of 24 patients (18 women and 6 men) were examined. Despite prior treatment with disease-modifying antirheumatic drugs, including methotrexate, patients with clinically active rheumatoid arthritis were recruited in two rheumatological centres to receive 40 mg adalimumab subcutaneously every other week. Clinical, laboratory and PDS assessments were carried out at 0, 2, 6 and 12 weeks. Clinical and laboratory measurements of disease activity included physician’s global assessment of disease activity, erythrocyte sedimentation rate and serum levels of C reactive protein. The Disease Activity Score for 28 joints (DAS28) was calculated. PDS signal was scored from 0 to 3 according to the overall expression of PDS findings at the wrists. Results: A significant reduction in both clinical (p,0.001) and PDS findings (p,0.001) was found at all follow-up examinations. A tendency to positive correlation (Spearman’s r = 0.382; p = 0.067) was shown between reduction in PDS score and improvement in DAS28 at week 2 examination. Conclusion: PDS detected a rapid and significant reduction in synovial perfusion at the wrist joints of patients with rheumatoid arthritis receiving adalimumab. Ongoing follow-up will provide further information regarding the persistence of considerable reduction in PDS signal score and its correlation with DAS28
2006
65
11
1433
1437
ANTITUMOR NECROSIS FACTOR, KNEE-JOINT, ULTRASONOGRAPHY, VASCULARITY, ULTRASOUND, THERAPY, FINGER, PANNUS, SCALE, US
FILIPPUCCI E; A. IAGNOCCO; SALAFFI F; CERIONI A; VALESINI G; GRASSI W
File in questo prodotto:
File Dimensione Formato  
173.pdf

Accesso aperto

Dimensione 608.35 kB
Formato Adobe PDF
608.35 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1613153
Citazioni
  • ???jsp.display-item.citation.pmc??? 20
  • Scopus 141
  • ???jsp.display-item.citation.isi??? 123
social impact